Willis Towers Watson (WLTW) Tops Q3 EPS by 19c, Revenues Beat; Offers FY18 EPS Guidance Above Consensus
Get Alerts WLTW Hot Sheet
Join SI Premium – FREE
Willis Towers Watson (NASDAQ: WLTW) reported Q3 EPS of $1.32, $0.19 better than the analyst estimate of $1.13. Revenue for the quarter came in at $1.89 billion versus the consensus estimate of $1.88 billion.
Excluding the Revenue Standard Impact
- Reported Revenue was $1.9 billion, an increase of 3%
- Organic Revenue increased 5%
- Net Income increased $139 million to $85 million or 4.5% of revenue.
- Adjusted EBITDA increased 14% to $368 million or 19.4% of revenue, a margin improvement of 200 basis points
- Diluted Earnings per Share increased 258% to $0.63
- Adjusted Diluted Earnings per Share increased 45% to $1.62
- Cash flows from operating activities for the nine months ended September 30, 2018 of $753 million
- Free Cash Flow for the nine months ended September 30, 2018 increased 72% to $544 million
Including the Revenue Standard Impact
- Reported Revenue was $1.9 billion
- Net Income was $46 million. Adjusted Net Income was $174 million
- Adjusted EBITDA was $313 million or 16.8% of revenue
- Diluted Earnings per Share were $0.33
- Adjusted Diluted Earnings per Share were $1.32
- Cash flows from operating activities for the nine months ended September 30, 2018 of $716 million
- Free Cash Flow for the nine months ended September 30, 2018 was $507 million
GUIDANCE:
Willis Towers Watson sees FY2018 EPS of $10.12-$10.32, versus the consensus of $9.58.
For earnings history and earnings-related data on Willis Towers Watson (WLTW) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share